Stocksigma LogoStocksigma Logo

Sai Life Sciences Reports Strong Q2 FY27 With Revenue Up 23% YoY

Sai Life Sciences posted consolidated revenue of ₹659 Cr in Q2 FY27, up 23% YoY, with EBITDA reaching ₹187 Cr (28% margin) and PAT rising 17% YoY to ₹98

Sai Life Sciences Reports Strong Q2 FY27 With Revenue Up 23% YoY

Sai Life Sciences Ltd · Investor Presentation · 06 Nov 2026, 5:47 am

Sai Life Sciences Reports Strong Q2 FY27 With Revenue Up 23% YoY Sai Life Sciences posted consolidated revenue of ₹659 Cr in Q2 FY27, up 23% YoY, with EBITDA reaching ₹187 Cr (28% margin) and PAT rising 17% YoY to ₹98 Cr. CDMO and CRO accounted for 64% and 36% of quarterly revenues, respectively, with capacity utilization at 67%. For H1 FY27, revenue climbed 17% YoY to ₹1,213 Cr, with EBITDA at ₹335 Cr and PAT of ₹172 Cr. Capex reached ₹621 Cr in H1 FY27, staying on track for the full-year target of ₹1,100–1,300 Cr.

Original exchange filing (PDF)

More announcements from Sai Life Sciences Ltd

All Sai Life Sciences Ltd announcements